Global Diversity
Array With
Cytogenetics

Global Diversity Array with Cytogenetics (GDA_Cyto) testing in oncology, including hematologic malignancies in blood and bone marrow and fresh and fixed (FFPE) solid tumors, provides information that can be critical for diagnosis, prognosis and treatment. GDA_Cyto detects copy number changes (deletion, duplication and amplification) on a scale from genome-wide to individual genes. In addition to oligonucleotides to detect copy number, the Cytogenomic microarray also contains single-nucleotide polymorphisms (SNPs) to uncover copy-neutral loss of heterozygosity (CN-LOH), associated with gene conversion in cancer.

Oxy-Gen Laboratory Targeted Gene and Region Panel Oncology Microarray is currently developed and available for targeted testing of the following conditions:

1.Glioma

2.Neuroblastoma

3.Wilms Tumors

4.Melanoma

5.Chronic Lymphocytic Leukemia (CLL)

In Addition, the GDA-Cyto Array is intended to aid in the diagnosis of chromosomal abnormalities associated with developmental disorders, including developmental delay (DD), intellectual disability (ID), multiple congenital anomalies (MCA), dysmorphic features, autism spectrum disorders (ASD), seizures, and epilepsy. This test reports detected whole and segmental aneuploidies, submicroscopic copy number variations (CNVs) that cannot be detected by conventional karyotype, size and gene content of CNVs, regions of homozygosity, and uniparental isodisomy.